Company intelligence / Profile preview

Gema Biotech S.A.

San Isidro / Olivos, Buenos Aires Province, Argentinavitrolife.com ↗

Ownership: Private
Employees: ~375
Development stage: Phase 3

Overview

Gema Biotech has advanced a biosimilar of follitropin alfa targeting infertility and is conducting a Phase 3 clinical trial of Enerceptan® in combination with methotrexate for rheumatoid arthritis. The status of these programs includes at least one pending approval and an ongoing or recently completed Phase 3 study, though some trial statuses are listed as "unknown."[1]

Therapeutic areas: Women's HealthRheumatology
Modalities: Recombinant proteinsBiosimilars (e.g., Follitropin alfa biosimilar)
Industry: Biotech

Drug pipeline

1 asset

Peg-Neutropine

Unknown

Beyond the preview

Go deeper on Gema Biotech S.A..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gema Biotech S.A..

Explore the full profile